BỘ KHOA HỌC VÀ CÔNG NGHỆ
HỆ THỐNG THÔNG TIN KHOA HỌC VÀ CÔNG NGHỆ

Lọc theo danh mục
  • Năm xuất bản
    Xem thêm
  • Lĩnh vực
liên kết website
Lượt truy cập
 Lượt truy cập :  22,581,123
  • Công bố khoa học và công nghệ Việt Nam

Ung thư học và phát sinh ung thư

Huỳnh Nhật Lễ, Lê Thanh Duy, Mai Thành Tấn(1), Trần Thành Đạo, Lê Minh Trí(3), Thái Khắc Minh(2)

Liệu pháp miễn dịch interleukin-2 trong điều trị ung thư

Tạp chí Y học TP. Hồ Chí Minh

2021

2-CD5

1-10

1859-1779

Ung thư, Interleukin-2, LIệu pháp miễn dịch, Điều trị

Interleukin -2 (IL-2) đã được biết đến và sử dụng trong điều trị ung thư di căn nhờ vào đặc tính kích thích các tế bào T từ đầu những năm 1980. Tuy nhiên, việc sử dụng IL-2 liều cao trong điều trị gây ra các dụng phụ nghiêm trọng trên tế bào nội mô mạch máu và hệ cơ quan dẫn đến thất bại trong điều trị. Chính điều này đã thúc đẩy việc nghiên cứu thiết kế các phân tử IL-2 tăng cường kích thích phản ứng kháng khối u cũng như giảm tác dụng phụ trên bệnh nhân. Trong bài viết này, các phương hướng cải thiện liệu pháp miễn dịch IL-2 được tóm tắt và bàn luận về tiềm năng của liệu pháp này trong tương lai.

TTKHCNQG, CVv 395

Xem toàn văn
  • [1] Klein C, Nicolini V, Seeber S, Lauener L, et al (2019), Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cisactivation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism.,Cancer Research,79(13):1552.
  • [2] KleinCI, Waldhauer VG, Nicolini A, Freimoser-Grundschober T, et al (2017), Cergutuzumab amunaleukin (CEA-IL2v), a CEAtargeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.,Oncoimmunology, 6(3):1277306.
  • [3] Pipeline P (2020), Oncology, pharma pipeline.,URL: https://www.roche.com/research_and_development/who_we_ar e_how_we_work/pipeline.htm (access on 21/01/2021)
  • [4] Biocentury (2011), Hu14.18-IL2 (APN301), Biocentury.,URL: https://bciq.biocentury.com/products/hu1418-il2_(apn301) (access on 21/01/2021).
  • [5] Biocentury (2019), Darleukin (L19-IL2), biocentury.,URL: https://bciq.biocentury.com/products/darleukin_(l19-il2) (access on 21/01/2021).
  • [6] Miura JT, Zager JS (2019), Neo-DREAM study investigating daromun for the treatment of clinical stage IIIB/C melanoma.,Future Oncol, 15(32):3665-3674
  • [7] Medicenna (2020), MDNA11- An Immune Activation Swich, Medicenna,,URL: https://www.medicenna.com/pipeline/mdna11/ (access on 21/01/2021)
  • [8] Silva DA, Yu S, Ulge UY, Spangler JB, et al. (2019), De novo design of potent and se-lective mimics of IL-2 and IL-15.,Nature, 565(7738):186-191.
  • [9] Rosen DB, Knappe T, Schnabel M, et al (2020), Abstract 4507: TransConTM IL-2 β/γ: a novel long-acting prodrug of receptorbiased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer.,American Association for Cancer Research, 80(16):4507
  • [10] Willem W, Overwijk MAT, Zalevsky J (2020), Engineering IL-2 to give new life to T cell immunotherapy.,Annual Reviews, 72(1):30.1-30.31
  • [11] C-harych DH, Hoch U, Langowski JL, et al (2016), NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models.,Clin Cancer Res, 22(3):680-690
  • [12] Arenas-Ramirez N, Zou C, Popp S, et al (2016), Improved cancer immunotherapy by a CD25-mimobody conferring se-lectivity to human interleukin-2.,Sci Transl Med, 8(367): 367-376.
  • [13] Arenas-Ramirez N, Woytschak J, Boyman O (2015), Interleukin-2: biology, design and application.,Trends Immunol, 36(12):763-777.
  • [14] Tomala J, Chmelova H, Mrkvan T, et al (2009), In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.,J Immunol, 183(8):4904-4912.
  • [15] Rosalia RA, Arenas-Ramirez N, Bouchaud G, et al (2014), Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer.,Curr Opin Chem Biol, 23:39-46
  • [16] Klein CI, Waldhauer VG, Nicolini A, Freimoser-Grundschober T, et al (2017), Cergutuzumab amunaleukin (CEA-IL2v), a CEAtargeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.,Oncoimmunology, 6(3):e1277306.
  • [17] Wang A, Lu SD, Mark DF (1984), Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.,Science, 224(4656):1431-1443
  • [18] Carmenate TA, Pacios M, Enamorado E, et al (2013), Human IL2 mutein with higher antitumor efficacy than wild type IL-2.,J Immunol, 190(12):6230-6238
  • [19] Carmenate TY, Ortiz M, Enamorado K, Garcia-Martinez J, et al (2018), Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells.,J Immunol, 200(10):3475-3484.
  • [20] Lopes JE, Fisher JL, Flick HL, Wang C, et al (2020), ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular se-lectivity profile for cancer immunotherapy.,J Immunother Cancer, 8(1).
  • [21] C-harych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, et al (2016), NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models.,Clin Cancer Res, 22(3):680-90
  • [22] Boyman O, Arenas-Ramirez N (2019), Development of a novel class of interleukin-2 immunotherapies for metastatic cancer.,Swiss Med Wkly, 149:14697.
  • [23] Kriega C, Pantaleoa G, Boymana O (2010), Improved IL-2 immunotherapy by se-lective stimulation of IL-2 receptors on lymphocytes and endothelial cells.,Proceedings of the National Academy of Sciences, 107(26):11906-11911.
  • [24] West WH, Tauer KW, Yannelli JR, Marshall GD, et al (1987), Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.,N Engl J Med, 316(15):898-905.
  • [25] Boyman O, Surh CD, Sprent J (2006), Potential use of IL-2/antiIL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.,Expert Opin Biol Ther, 6(12):1323-1331.
  • [26] Schwartz RN, StoverL, Dutcher JP (2002), Managing toxicities of high-dose interleukin-2.,Oncology (Williston Park), 16(11S13):11-20.
  • [27] Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ (1996), Mechanisms of interleukin-2-induced hepatic toxicity.,Cancer Res, 56(3):507-510
  • [28] Rosenberg SA, Lotze MT, Muul LM, Leitman S, et al (1985), Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.,N Engl J Med, 313(23):1485-1492
  • [29] Attias M, Al-Aubodah T (2019), Mechanisms of human FoxP3(+) T(reg) cell development and function in health and disease.,Clin Exp Immunol, 197(1):36-51
  • [30] Létourneau S, Krieg C, Pantaleo G, Boyman O (2009), (2009). IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.,J Allergy Clin Immunol, 123(4):758-762.
  • [31] Asao H (2014), Interleukin-2.,URL: https://www.sciencedirect.com/science/article/pii/B978012801238 3040587 (access on 21/01/2021).
  • [32] Gaffen SL (2001), Signaling domains of the interleukin 2 receptor.,Cytokine, 14(2):63-77
  • [33] Coombs S (2019), ALKS 4230: an investigational se-lective il-2 fusion protein, alkermers.,URL: https://investor.alkermes.com/static-files/e4d73271-6106-4aa3- b0c7-7b526c777223 (access on 10/08/2020).
  • [34] Minami Y, Kono T, Miyazaki T, Taniguchi T (1993), The IL-2 receptor complex: its structure, function, and target genes.,Annu Rev Immunol, 11:245-268.
  • [35] Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA (2006), Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor.,Proc Natl Acad Sci USA, 103(8):2788-2793
  • [36] Rosenberg SA (1988), The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.,Ann Surg, 208(2):121-135
  • [37] Boyman O, Sprent J (2012), The role of interleukin-2 during homeostasis and activation of the immune system.,Nat Rev Immunol, 12(3):180-190
  • [38] Schwartz RH (1992), Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.,Cell, 71(7):1065-1068.
  • [39] Rosenberg SA (2014), IL-2: the first effective immunotherapy for human cancer.,J Immunol, 192(12):5451-5458
  • [40] Gaffen SL, Liu KD (2004), Overview of interleukin-2 function, production and clinical applications.,Cytokine, 28(3):109-123